Molecular Diagnostics Market to Reach USD 43.69 Bn by 2032 as POC Testing, Oncology and AI Diagnostics Scale

Key Highlights

• The Molecular Diagnostics Market was valued at USD 26.96 Bn in 2025 and is forecast to reach nearly USD 43.69 Bn by 2032, making molecular testing a larger infrastructure decision for hospitals, labs and diagnostics firms.
• The market is expected to grow at a 7.14% CAGR from 2026 to 2032. That rate rewards companies that combine accuracy, speed, automation and clinical workflow fit.
• Reagents and kits held the largest product and service share in 2024 and are expected to remain dominant, supported by broad use in research and therapeutic settings.
• Lab tests held the largest share by test type, driven by automation needs, infectious disease burden and regulatory control in laboratory settings.
• PCR generated the largest technology revenue, while infectious disease diagnostics held the largest application share. That keeps molecular diagnostics tied to both outbreak response and routine clinical detection.

Why This Matters Now

Hospitals and laboratories are being forced to detect disease faster, with fewer errors and more treatment relevance. Molecular diagnostics now sits between outbreak control, cancer care, transplant monitoring and precision medicine.

Molecular Diagnostics Market rise from USD 26.96 Bn in 2025 to USD 43.69 Bn by 2032 signals a shift from conventional diagnostics toward genetic, proteomic and biomarker-led testing. For providers, this means faster clinical decisions. For manufacturers, it means competition will move from test availability to integrated platforms, regulatory execution and payer access.

Market Overview

Molecular diagnostics uses genetic and proteomic information to detect, diagnose, classify, prognose and monitor response to therapy. It applies molecular biology techniques to genetic polymorphisms, biomarkers, gene expression and protein analysis.

The market covers product and service categories including reagents and kits, instruments, and services and software. It also includes lab tests and point-of-care tests, with technologies such as PCR, INAAT, DNA sequencing and next-generation sequencing, in situ hybridization, DNA microarrays and other technologies.

The clinical use case is broad. Molecular diagnostics supports bacterial gene detection, infection-specific protein quantification, infectious disease diagnosis, oncology testing, genetic testing and treatment response monitoring. That makes it central to both acute care and long-term disease management.

Request Sample Report at: https://www.maximizemarketresearch.com/request-sample/610/

Key Trends Driving Growth

Point-of-care diagnostics is one of the strongest growth drivers. MMR links demand to recurring bacterial and viral epidemics, with COVID-19 accelerating rapid antigen and PCR-based diagnostics. The business implication is direct: decentralized testing is becoming a care-delivery requirement, not an emergency substitute.

Disease burden is adding volume and urgency. MMR cites tuberculosis and cancer prevalence, including 10.5 million individuals affected globally in 2023, with India and China identified among the major affected countries. It also states that global cancer incidence is expected to reach 28 million cases by 2040, making early detection and treatment selection a larger clinical and commercial priority.

Precision medicine is moving diagnostics closer to therapy decisions. Liquid biopsy, biomarker discovery, medication sensitivity testing and antibiotic resistance gene identification can shorten the time needed to select the right treatment. That benefits oncology centers, infectious disease teams and drug developers seeking companion diagnostic pathways.

Financial and regulatory barriers remain material. MMR cites FDA validation delays during COVID-19, high NGS platform costs of USD 500,000 to USD 1,000,000, annual NGS maintenance costs of USD 200,000 to USD 500,000, and reimbursement challenges for liquid biopsy tests such as Guardant Health assays. These constraints can slow adoption in smaller laboratories and restrict patient access to advanced testing.

Segment Insights

• Dominant Segment Reagents & Kits: Reagents and kits held the largest product and service revenue share in 2024 and are expected to continue leading. Their use in research and therapeutic settings supports standardized results, efficiency and cost-effectiveness.
• Dominant Test Type Lab Tests: Lab tests held the largest share by test type. Laboratory testing offers control over test intensity, regulatory compliance, repeatability and impartiality, making it critical for high-volume and complex diagnostics.
• Dominant Technology PCR: PCR generated the largest revenue by technology, supported by use in COVID-19 and other infectious disease diagnosis. High-throughput PCR is also used for viral and genetic disease detection.
• Dominant Application Infectious Disease Diagnostics: Infectious disease diagnostics held the largest application share. PCR and ISH have reduced the limitations of traditional testing, including long turnaround times, low sensitivity and difficulty cultivating organisms.
• Fastest-Growing Segment: The supplied MMR public page does not identify a fastest-growing segment by product, test type, technology, application or end user. No fastest-growing segment should be inferred.

Regional Growth Story

North America holds the leading position and is expected to maintain it through the forecast period. MMR links this to bacterial and viral disease outbreaks, rising point-of-care demand, rapid technology development and the presence of major molecular diagnostics companies.

The United States is central to this lead. During COVID-19, the U.S. used one-step PCR methods under CDC guidance, while rising healthcare spending per capita, better healthcare infrastructure, infectious disease incidence and cancer prevalence accelerated the move from traditional methods to molecular diagnostics.

Canada’s chronic disease burden, especially among the elderly, is expected to support demand for molecular diagnostic testing. Europe remains a major consumer and imports molecular diagnostic tools to strengthen healthcare capacity. The public page includes Germany and the UK in the regional scope, but it does not disclose country-level spending, reimbursement or regulatory data.

Asia Pacific is positioned as a fast-emerging market, supported by increasing healthcare expenditure, rising awareness and demand for advanced healthcare solutions. China, India, Japan and South Korea are included in the regional scope, but the public page provides no country-level market values or reimbursement detail.

Competitive Landscape

The market includes Abbott Laboratories, Danaher, Quest Diagnostics, Hologic, Thermo Fisher Scientific, Sysmex, BGI Group, Biocon, Mylab Discovery Solutions, Trivitron Healthcare, Roche, QIAGEN, bioMérieux, Siemens Healthineers, Illumina, BD, Agilent Technologies, Seegene, Exact Sciences, QuidelOrtho, Bio-Rad Laboratories and Myriad Genetics. This is a scale and specialization market, where platform breadth, assay design and installed laboratory relationships matter.

Abbott’s pending acquisition of Exact Sciences signals a direct push into cancer molecular diagnostics. It also predicts stronger consolidation pressure as large diagnostics groups seek oncology assets with screening, testing and data value.

Danaher’s partnership with AstraZeneca to develop AI-powered diagnostics links molecular testing with precision medicine and targeted cancer therapy. This signals a market where diagnostics companies must align earlier with pharma pipelines, not wait for post-launch testing demand.

Seegene’s CURECA and STAgora launch points to automation, data analysis and standardized reporting as the next competitive layer in syndromic testing. Thermo Fisher’s transplant-focused molecular test shows another route: using molecular monitoring to improve post-transplant medication timing and patient outcomes.

Request Sample Report at: https://www.maximizemarketresearch.com/request-sample/610/

Recent Developments

• 06 March 2026 Thermo Fisher Scientific: The company introduced a specialized molecular test to help transplant patients receive anti-rejection medication sooner. This signals growth in molecular monitoring beyond infection and oncology into transplant care.
• 26 February 2026 Insight Molecular Diagnostics: The company achieved final ISO 13485 certification for the GraftAssureDx test kit, enabling regulatory filings in the UK and EU. This supports commercialization of decentralized transplant monitoring.
• 22 January 2026 Abbott: Abbott announced the pending acquisition of Exact Sciences, expected to close in the second quarter of 2026. The deal strengthens Abbott’s position in cancer molecular diagnostics and raises pressure on rivals to secure oncology platforms.
• 05 August 2025 Seegene: Seegene unveiled CURECA and STAgora at ADLM 2025 to advance syndromic molecular testing. The platforms signal higher demand for high-throughput testing, automated analysis and standardized clinical reporting.
• 29 May 2025 Danaher and AstraZeneca: The companies partnered to develop AI-powered diagnostics for precision medicine. The collaboration links molecular diagnostics directly with targeted cancer therapy development.

Strategic Implications

For hospitals and diagnostic laboratories, molecular diagnostics is now a throughput and treatment-quality issue. Labs need platforms that support faster pathogen detection, cancer testing, transplant monitoring and genetic analysis without creating unsustainable cost or staffing burdens.

For pharma and biotech, diagnostics is moving into drug-development strategy. Companion diagnostics, AI-enabled test development and biomarker-led patient selection can shape trial design, therapy adoption and reimbursement discussions.

For payers and regulators, the unresolved issue is access. High equipment costs, specialist labor, reagent expenses and weak reimbursement for advanced assays can slow clinical adoption even when the test has strong medical value.

Future Outlook

The Molecular Diagnostics Market is forecast to grow from USD 26.96 Bn in 2025 to nearly USD 43.69 Bn by 2032 at a 7.14% CAGR. Growth will come from infectious disease testing, oncology, PCR, NGS, point-of-care diagnostics, transplant monitoring, AI-enabled companion diagnostics and broader adoption in emerging economies.

Future leaders will combine clinical accuracy, affordability, regulatory readiness and workflow integration; laggards will sell complex tests into a healthcare system that now demands speed, access and treatment relevance.

Related Report

Digestive Enzymes Market: https://www.maximizemarketresearch.com/market-report/global-digestive-enzymes-market/36264/

Orthopaedic Devices Market: https://www.maximizemarketresearch.com/market-report/orthopaedic-devices-market/11284/

Global CAR-T Cell Therapy Market: https://www.maximizemarketresearch.com/market-report/global-car-t-cell-therapy-market/98045/

Analyst Perspective

“Molecular diagnostics is becoming a clinical decision layer for infectious disease, oncology, transplant care and precision medicine,” said Komal Patil, Analyst at Maximize Market Research. “The strongest companies will pair accurate testing with automation, reimbursement access and faster integration into care pathways.”

About Maximize Market Research

Maximize Market Research Pvt. Ltd. (MMR) is a global market research and consulting company that provides reliable, data-focused, and practical business insights. The firm serves a wide range of industries, including healthcare, pharmaceuticals, technology, automotive, electronics, chemicals, personal care, and consumer goods. Through market forecasts, competitive analysis, strategic consulting, and industry impact assessments, MMR helps organizations understand changing market conditions, identify growth opportunities, and make informed business decisions for long-term success.

2nd Floor, Navale IT Park Phase 3

Pune Banglore Highway, Narhe

Pune, Maharashtra 411041, India

+91 9607365656

sales@maximizemarketresearch.com